



J. B. Chemicals & Pharmaceuticals Limited

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.

Phone: 022-2482 2222/2493 0918 Fax : 022 – 2493 0534/ 2493 9633

CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, November 4, 2015

Unaudited Financial Results for Q 2- 2015-16

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its standalone unaudited financial results for the quarter ended on September 30, 2015. The highlights of Y-o-Y results are as under:

(Rs. in crores)

Particulars	Q2-2015-16	Q2-2014-15
Net Sales	280.71	274.86
Other Operating income	6.07	5.40
Other Income	26.52	5.20
Total Income	313.30	285.46
EBIDTA	75.41	54.95
Operating Profit	38.85	39.73
Profit before tax	62.29	42.68
Profit after tax	48.99	31.89
EPS (Rs.) (FV 2)	5.78	3.76

The net sales for the quarter at Rs. 280.71 crores were marginally higher against net sales in the corresponding quarter in the previous year. The growth in top line was impacted due to overall lower exports. The PBT and PAT for the quarter at Rs. 62.29 crores and Rs. 48.99 crores were 45.93% and 53.62% higher respectively over corresponding quarter in the previous year.

The domestic formulations business at sales of Rs. 108.18 crores registered growth of 11.06%, while the focus products group achieved growth of 17%. The focus on cardiovascular products and topical preparations to drive the growth for the division during the year has met with good success. The contrast media products sales in domestic market at sales of Rs. 10.87 crores registered growth of 22.43%.

The overall formulations exports at Rs. 133.03 crores registered growth of 3.06% during the quarter. While the exports for Russia-CIS markets at Rs. 16.78 crores grew by 35.14%, the exports to Rest of the world markets at Rs. 88.63 crores were lower due to lower demand and uncertainty in many markets largely due to depreciation of local currency against US \$.

The API sales at Rs. 22.21 crores were lower. The product development income and other sales income during the quarter amounted to Rs. 6.42 crores.

Acquisition:

With a view to consolidate control and expand business in African continent, the board of directors has today also approved acquisition of 21,94,030 (51%) ordinary shares in Biotech Laboratories (Pty.) Ltd., South Africa ("Biotech"), held by Africa Biopharma Investments (Pty.) Ltd. by a company's subsidiary, subject to necessary approvals and definitive agreements to be entered into with the seller.

The company's subsidiary J.B. Healthcare Pvt. Ltd. presently holds 21,07,990 (49%) ordinary shares in Biotech, besides 175,591 Non-Redeemable Convertible Preference Shares. Post the proposed acquisition, conversion of preference shares and certain fresh issuance of ordinary shares by Biotech, the shareholding of the company's subsidiaries in Biotech will increase to over 95%.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine, CIS countries and South Africa. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D and regulatory set-up for development of new drug delivery system and formulations, filing of DMFs and ANDAs. Its State-of-the-Art manufacturing facilities are approved by health authorities of regulated markets.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary and Vice President- Compliance
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 2482 2311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.